AstraZeneca PLC (AZNCF)
132.93
-0.17
(-0.13%)
USD |
OTCM |
Oct 03, 15:55
AstraZeneca PS Ratio: 4.661 for Oct. 3, 2023
PS Ratio Chart
Historical PS Ratio Data
| Date | Value |
|---|---|
| October 02, 2023 | 4.667 |
| September 29, 2023 | 4.735 |
| September 28, 2023 | 4.774 |
| September 27, 2023 | 4.669 |
| September 26, 2023 | 4.732 |
| September 25, 2023 | 4.803 |
| September 22, 2023 | 4.836 |
| September 21, 2023 | 4.697 |
| September 20, 2023 | 4.780 |
| September 19, 2023 | 4.582 |
| September 18, 2023 | 4.609 |
| September 15, 2023 | 4.848 |
| September 14, 2023 | 4.663 |
| September 13, 2023 | 4.561 |
| September 12, 2023 | 4.636 |
| September 11, 2023 | 4.758 |
| September 08, 2023 | 4.758 |
| September 07, 2023 | 4.722 |
| September 06, 2023 | 4.695 |
| September 05, 2023 | 4.695 |
| September 01, 2023 | 4.769 |
| August 31, 2023 | 4.700 |
| August 30, 2023 | 4.794 |
| August 29, 2023 | 4.877 |
| August 28, 2023 | 4.791 |
| Date | Value |
|---|---|
| August 25, 2023 | 4.768 |
| August 24, 2023 | 4.769 |
| August 23, 2023 | 4.886 |
| August 22, 2023 | 4.762 |
| August 21, 2023 | 4.802 |
| August 18, 2023 | 4.770 |
| August 17, 2023 | 4.820 |
| August 16, 2023 | 4.823 |
| August 15, 2023 | 4.823 |
| August 14, 2023 | 5.021 |
| August 11, 2023 | 4.962 |
| August 10, 2023 | 4.837 |
| August 09, 2023 | 4.956 |
| August 08, 2023 | 4.956 |
| August 07, 2023 | 4.954 |
| August 04, 2023 | 4.917 |
| August 03, 2023 | 4.874 |
| August 02, 2023 | 4.878 |
| August 01, 2023 | 5.009 |
| July 31, 2023 | 5.078 |
| July 28, 2023 | 4.938 |
| July 27, 2023 | 4.925 |
| July 26, 2023 | 4.926 |
| July 25, 2023 | 4.807 |
| July 24, 2023 | 4.884 |
Price to Sales Ratio Definition
The Price to Sales Ratio (PS Ratio) is calculated by taking the stock price / revenue per share (ttm). This metric is considered a valuation metric that confirms whether the sales of a company justifies the stock price. There isn't necesarily an optimum PS ratio, since different industries will have different ranges of PS Ratios. Because of this, PS Ratio is great to evaluate from a relative standpoint with other similar companies. PS Ratio might also be a handy metric for companies that are not profitable yet, since they might be valued moreso by their overall sales and potential of becoming profitable in the future.
PS Ratio Range, Past 5 Years
3.666
Minimum
Sep 26 2022
6.173
Maximum
Jul 17 2020
4.874
Average
4.841
Median
Jul 31 2019
PS Ratio Benchmarks
| GSK PLC | 2.207 |
| Adaptimmune Therapeutics PLC | 1.823 |
| Akari Therapeutics PLC | -- |
| Biodexa Pharmaceuticals Plc | -- |
PS Ratio Related Metrics
| PE Ratio | 33.57 |
| Price to Book Value | 5.510 |
| Price to Free Cash Flow | 31.60 |
| Price | 132.93 |
| Earnings Yield | 2.98% |
| Market Cap | 206.03B |
| Operating PE Ratio | 31.89 |
| Normalized PE Ratio | 37.79 |